{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:40:05Z","timestamp":1776487205370,"version":"3.51.2"},"reference-count":31,"publisher":"Japanese Society of Internal Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,4,15]]},"DOI":"10.2169\/internalmedicine.5894-25","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T22:08:20Z","timestamp":1758146900000},"page":"1106-1114","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Practice of Treatment Switch in Transplant-eligible Patients with Multiple Myeloma: An Exploratory Retrospective Analysis"],"prefix":"10.2169","volume":"65","author":[{"given":"Sho","family":"Ikeda","sequence":"first","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Kitadate","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaya","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Omagari Kosei Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohito","family":"Fujishima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rhaumatology, Noshiro Kosei Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Nephrology, Akita City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Kume","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hiraka General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Kameoka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Akita Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kitabayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Akita Kosei Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Kuroki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yuri Kumiai General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Attal M, Lauwers-Cances V, Hulin C, et al.; the IFM 2009 Study. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 376: 1311-1320, 2017.","DOI":"10.1056\/NEJMoa1611750"},{"key":"2","unstructured":"2. Richardson PG, Jacobus SJ, Weller EA, et al.; the DETERMINATION Investigators. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 387: 132-147, 2022."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol 38: 1928-1937, 2020.","DOI":"10.1200\/JCO.19.02515"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Pasvolsky O, Wang Z, Milton DR, et al. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood Cancer J 14: 82, 2024.","DOI":"10.1038\/s41408-024-01062-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Chen Q, Zhang M, Zheng S, Tong Y, Tan Y. Therapeutic progress in relapsed\/refractory multiple myeloma. Ann Hematol 103: 1833-1841, 2024.","DOI":"10.1007\/s00277-024-05730-y"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Rocchi S, Zannetti BA, Marconi G, Lanza F. Multiple myeloma: the role of autologous stem cell transplantation in the era of immunotherapy. Cells 13: 853, 2024.","DOI":"10.3390\/cells13100853"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Chakraborty R, Siddiqi R, Willson G, et al. Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high-risk cytogenetics: a meta-analysis of randomized controlled trials. Cancer 128: 2288-2297, 2022.","DOI":"10.1002\/cncr.34211"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Harousseau JL, Avet-Loiseau H, Attal M, et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 27: 5720-5726, 2009.","DOI":"10.1200\/JCO.2008.21.1060"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Pasvolsky O, Marcoux C, Dai J, et al. Trends in outcomes after upfront autologous transplant for multiple myeloma over three decades. Transplant Cell Ther 30: 772.e1-772.e11, 2024.","DOI":"10.1016\/j.jtct.2024.06.001"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yimer H, Melear J, Faber E, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol 185: 492-502, 2019.","DOI":"10.1111\/bjh.15806"},{"key":"11","unstructured":"11. Mai EK, Bertsch U, Pozek E, et al. Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial. J Clin Oncol 43: 1279-1288, 2025."},{"key":"12","unstructured":"12. Sonneveld P, Dimopoulos MA, Boccadoro M, et al.; the PERSEUS Trial Investigators. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 390: 301-313, 2024."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol 97 Suppl 1: S3-S25, 2022.","DOI":"10.1002\/ajh.26512"},{"key":"14","unstructured":"14. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17: e328-e346, 2016."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Brioli A, Melchor L, Cavo M, Morgan GJ. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol 165: 441-454, 2014.","DOI":"10.1111\/bjh.12805"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol 14: 100-113, 2017.","DOI":"10.1038\/nrclinonc.2016.122"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Gaballa MR, Ma J, Tanner MR, et al. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma 63: 710-721, 2022.","DOI":"10.1080\/10428194.2021.1992763"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Byun JM, Park SS, Yoon SS, et al. Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study. Blood Res 58: 83-90, 2023.","DOI":"10.5045\/br.2023.2023005"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hydren JR, Sweeney NW, Sborov DW, et al. Real-world analysis of D-RVd v. RVd at induction for newly diagnosed transplant eligible multiple myeloma patients. J Clin Oncol 41 suppl 1: e20024, 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.e20024"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Shimazu Y, Kanda J, Suzuki K, et al. The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation. Cancer Sci 115: 2384-2395, 2024.","DOI":"10.1111\/cas.16198"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Chang H, Sloan S, Li D, et al. The t (4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 125: 64-68, 2004.","DOI":"10.1111\/j.1365-2141.2004.04867.x"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t (11;14) (q13;q32), t (4;14) (p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 106: 2837-2840, 2005.","DOI":"10.1182\/blood-2005-04-1411"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Cavo M, Terragna C, Renzulli M, et al. Poor outcome with front-line autologous transplantation in t (4;14) multiple myeloma: low complete remission rate and short duration of remission. J Clin Oncol 24: e4-e5, 2006.","DOI":"10.1200\/JCO.2005.04.7506"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Pasvolsky O, Ghanem S, Milton DR, et al. Outcomes of autologous stem cell transplantation in patients with ultra-high-risk multiple myeloma. Transplant Cell Ther 29: 757-762, 2023.","DOI":"10.1016\/j.jtct.2023.08.031"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 99: 1802-1824, 2024.","DOI":"10.1002\/ajh.27422"},{"key":"27","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s12885-024-12077-0","volume":"24","author":"Y Tao","year":"2024","unstructured":"27. Tao Y, Jin S, Yang D, et al. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma. BMC Cancer 24: 406, 2024.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kaiser MF, Sonneveld P, Cairns DA, et al. Co-occurrence of cytogenetic abnormalities and high-risk disease in newly diagnosed and relapsed\/refractory multiple myeloma. J Clin Oncol 43: 2679-2691, 2025.","DOI":"10.1200\/JCO-24-01253"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Stong N, Ortiz-Est\u00e9vez M, Towfic F, et al. The location of the t (4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM. Blood 141: 1574-1583, 2023.","DOI":"10.1182\/blood.2022016212"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, et al. Early relapse after autologous transplant is associated with very poor survival and identifies an ultra-high-risk group of patients with myeloma. Clin Lymphoma Myeloma Leuk 20: 445-452, 2020.","DOI":"10.1016\/j.clml.2019.10.014"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Matsuoka S, Osada N, Kubota H, et al. Discovery of a novel class NSD2 inhibitor for t(4;14)-positive multiple myeloma. Blood Neoplasia 2: 100091, 2025.","DOI":"10.1016\/j.bneo.2025.100091"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/8\/65_5894-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:51:08Z","timestamp":1776484268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/8\/65_5894-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5894-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"5894-25"}}